Italia markets closed

CLRB May 2024 2.500 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,80000,0000 (0,00%)
In data: 09:52AM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,8000
Aperto1,0000
Denaro0,4000
Lettera0,8500
Prezzo d'esercizio2,50
Scadenza2024-05-17
Min-Max giorno0,8000 - 1,0000
Contratto - Min-MaxN/D
Volume5
Open Interest428
  • GlobeNewswire

    Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants

    FLORHAM PARK, N.J., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced significant advancements to its global intellectual property (IP) portfolio. Cellectar has secured four patents across the key global regions Europe, Australia and Canada, covering the company’s proprietary Phospholipid Drug Conjug

  • GlobeNewswire

    Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia

    The EMA’s PRIME status is granted to drug candidates that may offer a major therapeutic advantage over existing treatments, or benefit patients without treatment optionsFLORHAM PARK, N.J., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that the European Medicines Agency (EMA) has granted Priority

  • GlobeNewswire

    Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing

    Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors Pivotal topline data in Waldenstrom’s macroglobulinemia expected in Q4 2023 with NDA submission and potential product launch in 2024 FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for th